(roe-mi-ploss-tim) ,


(trade name)


Therapeutic: temporary class
Pharmacologic: temporary class
Pregnancy Category: C


Treatment of thrombocytopenia associated with chronic immune (idiopathic) thrombocytopenic purpura that has not responded to corticosteroids, immunoglobulins, or splenectomy where there is risk of bleeding.


Acts as thrombopoetin (TPO) receptor agonist.

Therapeutic effects

Improved platelet count with decreased sequelae of thrombocytopenia (bleeding).


Absorption: Well absorbed following subcutaneous administration.
Distribution: Binds to specific cellular receptors.
Metabolism and Excretion: Unknown.
Half-life: 1–34 days.

Time/action profile

Subcutunknown1 wk2 wk


Contraindicated in: None noted.
Use Cautiously in: Hepatic or renal impairment; Geriatric: Elderly patients may be more sensitive to effects, escalate dose cautiously, consider concurrent disease states, age-related ↓ in organ function and drug therapy. Obstetric: May cause fetal harm, enroll in registry; avoid use during lactation; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • insomnia (most frequent)
  • headache


  • abdominal pain (most frequent)
  • dyspepsia


  • bone marrow fibrosis
  • thrombosis/thromboembolism (dose related)


  • extremity pain (most frequent)
  • myalgia (most frequent)
  • arthralgia
  • shoulder pain


  • paresthesia


  • angioedema (life-threatening)
  • hypersensitivity reactions (life-threatening)


Drug-Drug interaction

Drugs affecting platelet function should be avoided


Subcutaneous (Adults) 1 mcg/kg weekly, ↑ by 1 mcg/kg weekly to achieve and maintain platelet count of ≥ 50 x 109/L up to 10 mcg/kg.


Lyophilized powder for injection (requires reconstitution): 250 mcg/vial, 500 mcg/vial

Nursing implications

Nursing assessment

  • Assess for bruising and bleeding throughout therapy.
  • Lab Test Considerations: Monitor CBC, including platelet counts and peripheral blood smears, prior to, weekly until a stable platelet count (≥ 50 x 109/L for 4 wks without dose adjustment) is achieved, and at least monthly thereafter. If platelet count is <50 x 109/L, increase dose by 1 mcg/kg. If platelet count is >200 x 109/L for 2 consecutive weeks, decrease dose by 1 mcg/kg. If platelet count is >400 x 109/L, do not dose. Continue to assess platelet count weekly. When platelet count <200 x 109/L, resume romiplostim dose decreased by 1 mcg/kg. Do not administer if platelet count >400 X 109/L. Discontinue romiplostim if platelet count does not ↑ to sufficient level to avoid clinically important bleeding after 4 weeks of therapy at the maximum weekly dose of 10 mcg/kg. Continue monitoring for at least 2 wks following discontinuation. Excessive doses may increase risk of thrombolic/thromboembolic complications.
    • If platelet counts decrease following initial response, assess for formation of neutralizing antibodies. May require submitting blood samples to Amgen (1-800-772-6436) for assay.

Potential Nursing Diagnoses

Risk for injury (Indications)


  • Do not confuse romiplostim with romidepsin.
  • Adjust dose based on platelet count. If platelet count is <50 x 109/L, increase dose by 1 mcg/kg. If platelet count is >200 x 109/L for 2 consecutive wks, reduce dose by 1 mcg/kg. If platelet count is >400 x 109/L do not dose. Continue to assess platelet count weekly. After platelet count has fallen to <200 x 109/L, resume romiplostim at a dose reduced by 1 mcg/kg.
  • Subcutaneous: Administer as a subcut injection once weekly. Diluent: Reconstitute 250 mcg vial with 0.72 mL and 500 mcg vial with 1.2 mL of preservative-free Sterile Water for Injection. Concentration: 500 mcg/mL. Gently swirl vial to reconstitute; do not shake. Dissolution usually takes less than 2 min. Injection volume may be very small; use syringe with graduations to 0.01 mL. Solution is clear and colorless; do not administer solutions that are discolored or contain a precipitate. Protect solution from light. Reconstituted solution is stable at room temperature or if refrigerated for 24 hr. Discard unused portions of single-use vial. Do not administer more than one dose from each vial.
  • Romiplostim may be used with other therapies such as corticosteroids, danazol, azathioprine, immunoglobulin IV, and anti-D immunoglobulin.

Patient/Family Teaching

  • Explain purpose of romiplostim to patient. Advise patient to read Medication Guide prior to initiation of therapy. If a dose is missed, contact health care professional to arrange for next dose as soon as possible.
  • Instruct patient to notify health care professional of any bruising or bleeding that occurs during therapy or of any side effects that are bothersome or do not go away.
  • Advise patients to avoid situations or medications that may increase the risk of bleeding.
  • Advise patient to notify health care professional if pregnancy is planned or suspected. Inform pregnant patients of potential risks of therapy and encourage enrollment in pregnancy registry by calling 1-800-77-AMGEN (1-800-772-6436). Romiplostim should not be used while breastfeeding.
  • Emphasize the importance or repeated lab tests. Explain that platelet count will be monitored weekly until dose is stable, then tested monthly. When romiplostim is discontinued, platelet count will be monitored for at least 2 weeks to check if platelet count drops too low.

Evaluation/Desired Outcomes

  • Improved platelet count with decreased risk of bleeding. Discontinue if platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 wks at maximum weekly dose.
References in periodicals archive ?
One such novel agent is thrombopoietin receptor agonists like eltrombopag, romiplostim with promising results and lesser potential for immunogenicity.
Detailed review of the donor's medical history revealed a diagnosis of severe idiopathic thrombocytopenic purpura, refractory to treatment by corticosteroids, IV immunoglobulins, splenectomy (performed six months before organ harvesting), eltrombopag, and romiplostim.
More recently, recognising that platelet underproduction and megakaryocyte dysfunction play a substantial role in the pathophysiology of ITP, TPO receptor agonists such as romiplostim and eltrombopag have become available.
There are several second-line therapies: spelenectomy, rituximab, danazol, azathioprine, and thrombopoietin agonists such as eltrombopag and romiplostim.
Thrombopoietin analogues, particularly romiplostim, may be useful.
One treatment which worked for a time was a platelet boosting drug called Romiplostim.
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia (ITP).
The National Institute for Health and Clinical Excellence (Nice) has recommended the drug romiplostim (Nplate, Amgen) for chronic cases of the condition.
Under the agreement with Hypermarcas, Amgen reacquires the rights to several products, two of which are approved in Brazil--Vectibix (panitumumab) and Mimpara (cinacalcet)--and a third, romiplostim (Nplate in the U.
The availability of eltrombopag and romiplostim (AMG-531, Nplate), another new thrombopoietin receptor agonist, represents "a huge change" in thinking about ITP and will greatly benefit patients, according to Dr.
The role and safety of romiplostim in MDS has not been fully delineated.